We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+5.71%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$2.65B
AUM Growth
-$277M
Cap. Flow
+$27.9M
Cap. Flow %
1.06%
Top 10 Hldgs %
67.67%
Holding
75
New
11
Increased
7
Reduced
10
Closed
16

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$94.4M
2
SWTX
SpringWorks Therapeutics
SWTX
+$54.5M
3
QURE icon
uniQure
QURE
+$29.4M
4
ZYME icon
Zymeworks
ZYME
+$22.2M
5
XNCR icon
Xencor
XNCR
+$18.7M

Top Sells

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$51.5M
2
VRDN icon
Viridian Therapeutics
VRDN
+$44.6M
3
NUVB icon
Nuvation Bio
NUVB
+$44M
4
PCVX icon
Vaxcyte
PCVX
+$40.3M
5
EWTX icon
Edgewise Therapeutics
EWTX
+$33.4M

Sector Composition

Rank Sector Weight
1 Healthcare 94.51%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NMRA icon
26
Neumora Therapeutics
NMRA
$308M
$22M 0.83%
2,071,450
– –
CRGX
27
DELISTED
CARGO Therapeutics
CRGX
$21.2M 0.8%
1,470,000
– –
MLTX icon
28
MoonLake Immunotherapeutics
MLTX
$1.66B
$18M 0.68%
+332,522
New +$17M
DNA icon
29
Ginkgo Bioworks
DNA
$487M
$17.1M 0.65%
+1,743,344
New +$14.9M
RNAM
30
DELISTED
Avidity Biosciences
RNAM
$16.2M 0.61%
557,576
-200,000
-26% -$8.36M
MRSN
31
DELISTED
Mersana Therapeutics
MRSN
$16.2M 0.61%
453,120
-321,468
-42% -$16.6M
TCRX icon
32
TScan Therapeutics
TCRX
$50.2M
$15.2M 0.57%
5,000,000
– –
ADAP
33
DELISTED
Adaptimmune Therapeutics
ADAP
$14.8M 0.56%
27,404,070
– –
KYMR icon
34
Kymera Therapeutics
KYMR
$9.05B
$14.1M 0.53%
+350,000
New +$15.8M
DYN icon
35
Dyne Therapeutics
DYN
$4.24B
$13.1M 0.49%
555,644
– –
BCYC
36
Bicycle Therapeutics
BCYC
$276M
$12.7M 0.48%
910,000
– –
AVIR icon
37
Atea Pharmaceuticals
AVIR
$386M
$11.2M 0.42%
3,341,653
-2,100,243
-39% -$6.98M
DAWN
38
DELISTED
Day One Biopharmaceuticals
DAWN
$10.9M 0.41%
862,068
– –
REPL icon
39
Replimune Group
REPL
$724M
$10.3M 0.39%
850,341
– –
ALGS icon
40
Aligos Therapeutics
ALGS
$25.2M
$10.2M 0.38%
255,573
– –
ATRA icon
41
Atara Biotherapeutics
ATRA
$69.5M
$7.08M 0.27%
532,134
+63,196
+13% +$666K
VERV
42
DELISTED
Verve Therapeutics
VERV
$7.05M 0.27%
1,250,000
– –
QURE icon
43
CALL
uniQure
QURE
$2.63B
$6.8M 0.26%
+385,000
New +$3.32M
FATE icon
44
Fate Therapeutics
FATE
$283M
$5.03M 0.19%
+3,049,405
New +$7.68M
LKFT
45
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.84B
$4.26M 0.16%
155,006
– –
KLRS
46
Kalaris Therapeutics
KLRS
$85.2M
$3.95M 0.15%
17,769
-473,300
-96% -$7.16M
KROS icon
47
Keros Therapeutics
KROS
$202M
$2.97M 0.11%
187,500
– –
RLAY icon
48
Relay Therapeutics
RLAY
$4.06B
$2.64M 0.1%
641,426
-1,858,574
-74% -$10.1M
DSGN icon
49
Design Therapeutics
DSGN
$742M
$2.63M 0.1%
426,683
+372,849
+693% +$2.16M
NUVB.WS
50
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$2.56M 0.1%
963,333
– –
1
2
3

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return
CIP
Cornerstone Investment Partners Atlanta, Georgia $2.38B AUM 32.49% 1-Year Est. Return

EcoR1 Capital's Q4 2024 Portfolio in Review

As of Q4 2024, EcoR1 Capital held 75 positions worth $2.65B, down 9.5% from $2.92B the previous quarter. Its ten largest holdings account for 68% of the portfolio.

EcoR1 Capital's Q4 2024 filing shows 11 new, 7 increased, 10 reduced and 16 closed positions. Its largest new stake was Sarepta Therapeutics: 770,000 shares worth $93.6M. The largest sale was Centessa Pharmaceuticals, an estimated $51.5M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 100% a quarter earlier.

  • EcoR1 Capital's largest Q4 2024 buy was Sarepta Therapeutics: 770,000 shares worth $93.6M.
  • EcoR1 Capital added most to Zymeworks in Q4 2024, an estimated $22.2M increase.
  • EcoR1 Capital's biggest Q4 2024 reduction was Kura Oncology, cutting an estimated $32.4M.
  • EcoR1 Capital fully exited Centessa Pharmaceuticals in Q4 2024, selling an estimated $51.5M.
  • EcoR1 Capital's ten largest holdings make up 68% of its $2.65B portfolio in Q4 2024.
  • EcoR1 Capital opened 11 new positions and closed 16 in Q4 2024.
  • EcoR1 Capital's portfolio value fell 9.5% quarter-over-quarter to $2.65B.

Based on EcoR1 Capital's 13F filing for Q4 2024, filed 14 Feb 2025.